سعر افيشيست 2% 100 مل شراب للأطفال والرضع 2022

Carbocisteine 2% (100 mg/5 ml) syrup, 100 ml bottle (Avichest, listed under Sanofi in Egypt); mucolytic for children.

• Bronchial secretion disorders, especially in acute bronchial conditions: acute bronchitis and acute episodes of chronic bronchopneumopathy.Population: Children over 2 yearsBase de données publique des médicaments (ANSM, France)

• Risk of bronchial congestion in infants; epigastric discomfort; gastrointestinal disorders (gastralgia, nausea, vomiting, diarrhoea - dose reduction advised); gastrointestinal bleeding (stop treatment); allergic skin eruptions and anaphylactic reactions (pruritus, erythematous rash, urticaria, angioedema); fixed drug eruption; isolated cases of bullous dermatoses such as Stevens-Johnson syndrome and erythema multiforme.International label, same formulation · Base de données publique des médicaments (ANSM, France)

• Hypersensitivity to carbocisteine or any excipient (in particular methyl parahydroxybenzoate and other parabens).International label, same formulation · Base de données publique des médicaments (ANSM, France)
• Active gastroduodenal ulcer.International label, same formulation · Base de données publique des médicaments (ANSM, France)
• Infants under 2 years of age.International label, same formulation · Base de données publique des médicaments (ANSM, France)

• Re-evaluate the clinical situation in case of purulent sputum, fever, or chronic bronchial/lung disease; productive cough is a defence mechanism and should be respected.International label, same formulation · Base de données publique des médicaments (ANSM, France)
• Combining bronchial mucolytics with antitussives and/or drying (atropinic) agents is irrational.International label, same formulation · Base de données publique des médicaments (ANSM, France)
• Caution in the elderly, patients with a history of gastroduodenal ulcer, or with concomitant drugs that may cause gastrointestinal bleeding; stop treatment if bleeding occurs.International label, same formulation · Base de données publique des médicaments (ANSM, France)

• Antitussives and atropinic (secretion-drying) agentsNot a pharmacokinetic interaction (section 4.5 states none), but the RCP warns that combining mucolytics with antitussives and/or atropinic drying agents is irrational.Base de données publique des médicaments (ANSM, France)
• Drugs that may cause gastrointestinal bleedingCaution recommended when co-administered; stop carbocisteine if gastrointestinal bleeding occurs.Base de données publique des médicaments (ANSM, France)

• Animal studies showed no teratogenic effect, but no data are available in pregnant women; use during pregnancy is therefore not advised.International label, same formulation · Base de données publique des médicaments (ANSM, France)
• No data on excretion of carbocisteine into breast milk; use during breastfeeding is therefore not advised.International label, same formulation · Base de données publique des médicaments (ANSM, France)

• Carbocisteine: Mucoregulator acting on the gel phase of mucus, probably by breaking disulfide bridges of glycoproteins, which facilitates expectoration; in animal models it normalises the composition of secreted mucus glycoprotein and reduces goblet-cell hyperplasia.